[Translation] Multicenter, prospective, central randomization, open-label, endpoint of recombinant human TNK tissue plasminogen activator for injection (rhTNK-tPA, Mingfule) in the treatment of hyperacute ischemic stroke (onset <4.5h) Blind, active drug parallel control, non-inferior phase III clinical trial
评价rhTNK-tPA(0.25 mg/kg )对比标准rt-PA(0.9mg/kg)治疗超急性期缺血性卒中(发病<4.5h)的有效性和安全性。
[Translation] To evaluate the efficacy and safety of rhTNK-tPA (0.25 mg/kg) versus standard rt-PA (0.9 mg/kg) in the treatment of hyperacute ischemic stroke (onset <4.5h).